ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021

1 / 2 PRESSE RELEASE Lyon, June 2nd, 2021 ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021) 7.30am CEST- ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides, today announced an oral presentation on the bi-hormonal treatment M1Pram (ADO09) at the 14th International Conference on Advanced Technologies and Treatments for Diabetes ( ATTD 2021 ), which will be held June 2-5, 2021 as a virtual event. You will find below detailed information on the presentation: • Session: 0060 - Oral Presentation 02 Date & Time: Wednesday 2 June 7.45pm – 7.55pm CEST Room: Hall B Oral Presentation: #498 - ADO09, A CO-FORMULATION OF PRAMLINTIDE AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE (PPG) VERSUS INSULIN ASPART IN TYPE 1 DIABETES (T1D) Duration: 10 min About ATTD ATTD a scientific program that brings together renowned international ex perts to discuss major advances in diabetes treatments, technological innovations and present the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and more. About Adocia Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes, obesity and metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products and several pre -clinical products. The proprietary BioChaperone® 2 / 2 technological platform is desi gned to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. Adocia’s clinical pipeline includes four novel insulin formulation s for prandial treatment of diabetes: two ultra- rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone® Combo) and one combination of a prandia l insulin with amylin analog pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia. Adocia preclinical pipeline includes bi-hormonal combinations for diabetes treatment: two combinations of rapid acting insulin analogs and Pramlintide (BioChaperone® Lispro Pram and BioChaperone® Aspart Pram), a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In addition, there are two bi -hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® Glucagon Exenatide) and a combination of pramlintide and exenatide (PramExe). Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes. The first patent application supporting this program has been filed. Contact Adocia Adocia Gérard Soula CEO [email protected] Ph: +33 4 72 610 610 www.adocia.com MC Services AG Adocia Press Relations Europe Raimund Gabriel Managing Partner [email protected] Ph: +49 89 210 228 0 The Ruth Group Adocia Investor Relations USA James Salierno Vice-President [email protected] Ph.: +1 646 536 7035 Disclaimer This press release contains certain forward -looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contai ned in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the “Risk Factors” section of the Universal Registration Document filed with the French Autorité des marchés financiers on April 20, 2021 (a copy of which is available at www.adocia.com) and to the development of economic conditions financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.

The release as fetched from its publisher. adocia.com ↗